Your browser doesn't support javascript.
loading
Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018.
Mallinson, David C; Kuo, Hsiang-Hui Daphne; Kirby, Russell S; Wang, Yi; Berger, Lawrence M; Ehrenthal, Deborah B.
Afiliación
  • Mallinson DC; Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States of America. Electronic address: dmallinson@wisc.edu.
  • Kuo HD; Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States of America.
  • Kirby RS; The Chiles Center, College of Public Health, University of South Florida, Tampa, FL, United States of America.
  • Wang Y; Silberman School of Social Work, Hunter College, New York, NY, United States of America.
  • Berger LM; Sandra Rosenbaum School of Social Work, University of Wisconsin-Madison, Madison, WI, United States of America.
  • Ehrenthal DB; Department of Biobehavioral Health, The Pennsylvania State University, University Park, PA, United States of America; Social Science Research Institute, The Pennsylvania State University, University Park, PA, United States of America.
Prev Med ; 181: 107914, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38408650
ABSTRACT

OBJECTIVE:

The difference in infant health outcomes by maternal opioid use disorder (OUD) status is understudied. We measured the association between maternal OUD during pregnancy and infant mortality and investigated whether this association differs by infant neonatal opioid withdrawal syndrome (NOWS) or maternal receipt of medication for OUD (MOUD) during pregnancy.

METHODS:

We sampled 204,543 Medicaid-paid births from Wisconsin, United States (2010-2018). The primary exposure was any maternal OUD during pregnancy. We also stratified this exposure on NOWS diagnosis (no OUD; OUD without NOWS; OUD with NOWS) and on maternal MOUD receipt (no OUD; OUD without MOUD; OUD with <90 consecutive days of MOUD; OUD with 90+ consecutive days of MOUD). Our outcome was infant mortality (death at age <365 days). Demographic-adjusted logistic regressions measured associations with odds ratios (OR) and 95% confidence intervals (CI).

RESULTS:

Maternal OUD was associated with increased odds of infant mortality (OR 1.43; 95% CI 1.02-2.02). After excluding infants who died <5 days post-birth (i.e., before the clinical presentation of NOWS), regression estimates of infant mortality did not significantly differ by NOWS diagnosis. Likewise, regression estimates did not significantly differ by maternal MOUD receipt in the full sample.

CONCLUSIONS:

Maternal OUD is associated with an elevated risk of infant mortality without evidence of modification by NOWS nor by maternal MOUD treatment. Future research should investigate potential mechanisms linking maternal OUD, NOWS, MOUD treatment, and infant mortality to better inform clinical intervention.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Buprenorfina / Síndrome de Abstinencia Neonatal / Trastornos Relacionados con Opioides Límite: Female / Humans / Infant / Newborn / Pregnancy País/Región como asunto: America do norte Idioma: En Revista: Prev Med Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Buprenorfina / Síndrome de Abstinencia Neonatal / Trastornos Relacionados con Opioides Límite: Female / Humans / Infant / Newborn / Pregnancy País/Región como asunto: America do norte Idioma: En Revista: Prev Med Año: 2024 Tipo del documento: Article